Cargando…
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manage due to many factors. Beginning with the introduction of fluoxetine to the United States in 1988, sele...
Autores principales: | Edinoff, Amber N., Akuly, Haseeb A., Hanna, Tony A., Ochoa, Carolina O., Patti, Shelby J., Ghaffar, Yahya A., Kaye, Alan D., Viswanath, Omar, Urits, Ivan, Boyer, Andrea G., Cornett, Elyse M., Kaye, Adam M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395812/ https://www.ncbi.nlm.nih.gov/pubmed/34449705 http://dx.doi.org/10.3390/neurolint13030038 |
Ejemplares similares
-
Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021) -
Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
por: Maini, Kunal, et al.
Publicado: (2021) -
Updated Perspectives on the Neurobiology of Substance Use Disorders Using Neuroimaging
por: Murnane, Kevin S, et al.
Publicado: (2023)